Cell Therapeutics, Inc. Management to Discuss Today's Announcement
of Interim Pixantrone Study Results
SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to
discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...
Advanced Life Sciences to Host Conference Call to Discuss Data From
Cethromycin's First of Two Phase 3 Pneumonia Trials
CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced that it will host aconference call and live webcast at 10:00 am (EDT) on Monday, July2, 2007 to
discuss data from Trial CL-06, the first of two pivotalPhase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatment...
Medivation to Host Conference Call to Discuss Top-Line 12-Month
Results From Dimebon Alzheimer's Disease Study
SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that it will hold a teleconferenceat 8:30 a.m. Eastern time on Monday, June 11, to
discuss top-line12-month results from its randomized, double-blind,placebo-controlled Phase 2 clinical trial of Dimebon(TM), its leadproduct candidate, in Alzheimer's disease. Rachelle Doody, M.D., Ph.D., lead inve...
Clinical Trial Results Change Standard of Care for Pancreatic
Cancer Patients, Future Therapies Discussed
CHICAGO, June 05, 2007 /PRNewswire-USNewswire/ -- The BarbaraAnn Karmanos Cancer Institute's Philip A. Philip, M.D., Ph.D.F.R.C.P., professor of medicine and oncology, presented the outcomeof one of the largest randomized phase III pancreas cancer clinicaltrials in North America and chaired an education session about thefuture of pancreatic cancer therapies at the American Society ofClin...
2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with
AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
REGENSBURG, Germany, May 10th, 2007 - AntisensePharma, a German biopharmaceutical company specialized in targetedtherapies for malignant tumors, today announced, that data from thePhase IIb-study with AP 12009 in high-grade glioma will bepresented at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO), which will be held in Chicago, Illinois,U.S.A, fro...
Helix BioMedix to Discuss Potential of Its Proprietary Peptides at
the BIO International Convention
BOTHELL, Wash., April 18, 2007 /PRNewswire-FirstCall/ -- HelixBioMedix, Inc. today announced that Timothy Falla, Ph.D, ChiefScientific Officer, will present an update on the company's newgeneration of small molecule peptide (lipohexapeptide) technologyat the BIO International Convention. The convention will take placeat the Boston Convention & Exhibition Center in Boston, MA fromMay...